Eli Lilly (LLY)

The American labor market is experiencing a fascinating dichotomy as it navigates late 2024 and 2025. While overall job creation has shown signs of moderation and significant revisions to earlier optimistic figures, a robust undercurrent of growth is emerging from the nation's manufacturing sector. This resurgence, largely driven by substantial

New York, NY – December 9, 2025 – The S&P 500 Healthcare sector found itself in a precarious position today, emerging as the biggest underperformer among its peers. While the broader S&P 500 index largely treaded water, the healthcare segment registered a notable decline of 0.5%, extending a three-day

Eli Lilly is expanding its U.S. manufacturing footprint with a new Alabama facility that will add thousands of jobs.

As global trade tensions escalate dramatically throughout late 2024 and 2025, marked by a surge in protectionist policies and tit-for-tat tariffs, silver has emerged as a dual-threat asset: a critical safe-haven for investors fleeing economic uncertainty and a strategic industrial metal indispensable to the burgeoning green and high-tech economies. With

A new revenue driver may be just ahead.

Global financial markets are treading a cautious path as December 9, 2025, unfolds, with investors keenly focused on the impending U.S. Federal Reserve's interest rate decision. The highly anticipated move, expected to be a 25-basis-point cut, is poised to reshape monetary policy landscapes, while persistent geopolitical tensions and the

Blockbuster drugs are a major driver of the growth of healthcare stocks.

JPMorgan Chase & Co. (NYSE: JPM), a titan of the financial industry and a significant component of the Dow Jones Industrial Average (DJIA), recently experienced a notable shift in market sentiment. Despite a year of robust financial performance characterized by surging earnings and revenue growth throughout 2024 and 2025, a cautious

Here are some things I think are more likely to happen in 2026 than the experts seem to believe.

After experiencing incredible rallies during 2025, these two stocks could decide to "split it" in 2026.

It continues to be pounded by competition and challenges coming from numerous directions.

Market-based odds now show an 87% chance of a rate cut.

Eli Lilly and Co (NYSE: LLY) announced that its diabetes drug, Mounjaro, will be added to China's state-run health insurance scheme from January 1, 2026.

This is no reason to panic.

Eli Lilly offers a stable, growing dividend backed by exceptional profitability and solid financial health, making it a prime pick for long-term dividend growth investors.

These three drugmakers are all well off their recent highs. Is this a sign of opportunity or risk?

Eli Lilly's stock price and market cap are poised to explode with the GLP-1 market.

The issues are piling on for the healthcare leader, but this one is nowhere near insurmountable.

Surging stock prices and earnings growth potential make Meta Platforms, ASML, and Eli Lilly ripe for stock splits in the new year.

The report added that at least one of these companies expects to fulfill the multi-billion-dollar investment pledge in full by Jan. 1, 2029.

Despite Agilent Technologies’ underperformance relative to its industry peers, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Eli Lilly has decided to slash prices of its weight loss drug Zepbound, making it more accessible to customers.

A key catalyst may be right around the corner.